Zoledronic acid to prevent bone loss in Chinese men receiving androgen deprivation therapy for prostate cancer
Aim: To explore the bone mineral density (BMD) preservation effect of zoledronic acid and its renal safety and tolerability in Chinese patients with prostate cancer on androgen deprivation therapy (ADT). Methods: Overall 26 prostate cancer patients with ADT were given zoledronic acid 4 mg by a 15‐...
Gespeichert in:
| Veröffentlicht in: | Asia-Pacific journal of clinical oncology 2011-06, Vol.7 (2), p.168-173 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 173 |
|---|---|
| container_issue | 2 |
| container_start_page | 168 |
| container_title | Asia-Pacific journal of clinical oncology |
| container_volume | 7 |
| creator | YEE, Chi-hang NG, Chi-fai WONG, Annie YF CHAN, Chi-kowk HOU, See-ming YIP, Sidney KH |
| description | Aim: To explore the bone mineral density (BMD) preservation effect of zoledronic acid and its renal safety and tolerability in Chinese patients with prostate cancer on androgen deprivation therapy (ADT).
Methods: Overall 26 prostate cancer patients with ADT were given zoledronic acid 4 mg by a 15‐min i.v. infusion every 3 months for up to 12 months. Assessment was made at baseline and at 3, 6, 9 and 12 months. Dual‐energy X‐ray absorptiometry was used to measure the BMD of the lumbar spine and the femoral neck at baseline and 12 months.
Results: A total of 23 of 26 recruited patients completed the study. Seven patients had bone metastases. The overall mean increase in BMD (T‐score) of the lumbar spine and femoral head from baseline to follow up at 12 months was significant (−2.32 ± 0.98 to −2.03 ± 1.08, P = 0.02 and −1.77 ± 0.72 to −1.63 ± 0.76, P = 0.01, respectively). In subgroup analyses, significant BMD improvement was observed independent of the status of bone metastasis and the means of ADT. Zoledronic acid had no adverse effect on renal function. Adverse events related to zoledronic acid were minimal.
Conclusion: Zoledronic acid administered every 3 months significantly increased BMD in prostate cancer patients receiving ADT. It had a satisfactory adverse event profile and imposed minimal risk on patients' renal function. |
| doi_str_mv | 10.1111/j.1743-7563.2011.01388.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_867725372</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>867725372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4078-7dc83404743f96043b90348dab24f8bb1d79daa97ea2d579dfd934bb7e3a4ce93</originalsourceid><addsrcrecordid>eNqNkE9vEzEQxS1ERf_AV0C-cdqtvfauvRekkkKgragUgZC4WF57tnXY2MHehOTb4yVtzvji0fi9N-MfQpiSkuZzuSyp4KwQdcPKilBaEsqkLHcv0Nnx4eWxrutTdJ7SkhDWVi19hU4rWsu6acUZ8j_DADYG7wzWxlk8BryOsAU_4i54wENICTuPZ4_OQwK8Ao8jGHBb5x-w9tn7kFsW1tFt9eiCx-MjRL3e4z7EnBXSqEfARnsD8TU66fWQ4M3TfYG-f_r4bfa5uLuff5ld3RWGEyELYY1knPC8f982hLOuJYxLq7uK97LrqBWt1boVoCtb57q3LeNdJ4BpbqBlF-jdITfP_72BNKqVSwaGQXsIm6RkI0RVM1FlpTwoTd40RehV_shKx72iRE2w1VJNHNXEVE2w1T_Yapetb5-GbLoV2KPxmW4WvD8I_rgB9v8drK5uZvdTmQOKQ4BLI-yOATr-Uo1golY_vs7V9XyxuP5AFuqW_QUlD58d</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>867725372</pqid></control><display><type>article</type><title>Zoledronic acid to prevent bone loss in Chinese men receiving androgen deprivation therapy for prostate cancer</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>YEE, Chi-hang ; NG, Chi-fai ; WONG, Annie YF ; CHAN, Chi-kowk ; HOU, See-ming ; YIP, Sidney KH</creator><creatorcontrib>YEE, Chi-hang ; NG, Chi-fai ; WONG, Annie YF ; CHAN, Chi-kowk ; HOU, See-ming ; YIP, Sidney KH</creatorcontrib><description>Aim: To explore the bone mineral density (BMD) preservation effect of zoledronic acid and its renal safety and tolerability in Chinese patients with prostate cancer on androgen deprivation therapy (ADT).
Methods: Overall 26 prostate cancer patients with ADT were given zoledronic acid 4 mg by a 15‐min i.v. infusion every 3 months for up to 12 months. Assessment was made at baseline and at 3, 6, 9 and 12 months. Dual‐energy X‐ray absorptiometry was used to measure the BMD of the lumbar spine and the femoral neck at baseline and 12 months.
Results: A total of 23 of 26 recruited patients completed the study. Seven patients had bone metastases. The overall mean increase in BMD (T‐score) of the lumbar spine and femoral head from baseline to follow up at 12 months was significant (−2.32 ± 0.98 to −2.03 ± 1.08, P = 0.02 and −1.77 ± 0.72 to −1.63 ± 0.76, P = 0.01, respectively). In subgroup analyses, significant BMD improvement was observed independent of the status of bone metastasis and the means of ADT. Zoledronic acid had no adverse effect on renal function. Adverse events related to zoledronic acid were minimal.
Conclusion: Zoledronic acid administered every 3 months significantly increased BMD in prostate cancer patients receiving ADT. It had a satisfactory adverse event profile and imposed minimal risk on patients' renal function.</description><identifier>ISSN: 1743-7555</identifier><identifier>EISSN: 1743-7563</identifier><identifier>DOI: 10.1111/j.1743-7563.2011.01388.x</identifier><identifier>PMID: 21585697</identifier><language>eng</language><publisher>Melbourne, Australia: Blackwell Publishing Asia</publisher><subject>Aged ; Androgen Antagonists - adverse effects ; androgen deprivation therapy ; Asian Continental Ancestry Group ; Bone Density - drug effects ; Bone Density Conservation Agents - therapeutic use ; Diphosphonates - therapeutic use ; Humans ; Imidazoles - therapeutic use ; Male ; Orchiectomy - adverse effects ; Osteoporosis - chemically induced ; Osteoporosis - prevention & control ; prostate cancer ; Prostatic Neoplasms - drug therapy ; zoledronic acid</subject><ispartof>Asia-Pacific journal of clinical oncology, 2011-06, Vol.7 (2), p.168-173</ispartof><rights>2011 Blackwell Publishing Asia Pty Ltd</rights><rights>2011 Blackwell Publishing Asia Pty Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4078-7dc83404743f96043b90348dab24f8bb1d79daa97ea2d579dfd934bb7e3a4ce93</citedby><cites>FETCH-LOGICAL-c4078-7dc83404743f96043b90348dab24f8bb1d79daa97ea2d579dfd934bb7e3a4ce93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1743-7563.2011.01388.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1743-7563.2011.01388.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21585697$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>YEE, Chi-hang</creatorcontrib><creatorcontrib>NG, Chi-fai</creatorcontrib><creatorcontrib>WONG, Annie YF</creatorcontrib><creatorcontrib>CHAN, Chi-kowk</creatorcontrib><creatorcontrib>HOU, See-ming</creatorcontrib><creatorcontrib>YIP, Sidney KH</creatorcontrib><title>Zoledronic acid to prevent bone loss in Chinese men receiving androgen deprivation therapy for prostate cancer</title><title>Asia-Pacific journal of clinical oncology</title><addtitle>Asia Pac J Clin Oncol</addtitle><description>Aim: To explore the bone mineral density (BMD) preservation effect of zoledronic acid and its renal safety and tolerability in Chinese patients with prostate cancer on androgen deprivation therapy (ADT).
Methods: Overall 26 prostate cancer patients with ADT were given zoledronic acid 4 mg by a 15‐min i.v. infusion every 3 months for up to 12 months. Assessment was made at baseline and at 3, 6, 9 and 12 months. Dual‐energy X‐ray absorptiometry was used to measure the BMD of the lumbar spine and the femoral neck at baseline and 12 months.
Results: A total of 23 of 26 recruited patients completed the study. Seven patients had bone metastases. The overall mean increase in BMD (T‐score) of the lumbar spine and femoral head from baseline to follow up at 12 months was significant (−2.32 ± 0.98 to −2.03 ± 1.08, P = 0.02 and −1.77 ± 0.72 to −1.63 ± 0.76, P = 0.01, respectively). In subgroup analyses, significant BMD improvement was observed independent of the status of bone metastasis and the means of ADT. Zoledronic acid had no adverse effect on renal function. Adverse events related to zoledronic acid were minimal.
Conclusion: Zoledronic acid administered every 3 months significantly increased BMD in prostate cancer patients receiving ADT. It had a satisfactory adverse event profile and imposed minimal risk on patients' renal function.</description><subject>Aged</subject><subject>Androgen Antagonists - adverse effects</subject><subject>androgen deprivation therapy</subject><subject>Asian Continental Ancestry Group</subject><subject>Bone Density - drug effects</subject><subject>Bone Density Conservation Agents - therapeutic use</subject><subject>Diphosphonates - therapeutic use</subject><subject>Humans</subject><subject>Imidazoles - therapeutic use</subject><subject>Male</subject><subject>Orchiectomy - adverse effects</subject><subject>Osteoporosis - chemically induced</subject><subject>Osteoporosis - prevention & control</subject><subject>prostate cancer</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>zoledronic acid</subject><issn>1743-7555</issn><issn>1743-7563</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE9vEzEQxS1ERf_AV0C-cdqtvfauvRekkkKgragUgZC4WF57tnXY2MHehOTb4yVtzvji0fi9N-MfQpiSkuZzuSyp4KwQdcPKilBaEsqkLHcv0Nnx4eWxrutTdJ7SkhDWVi19hU4rWsu6acUZ8j_DADYG7wzWxlk8BryOsAU_4i54wENICTuPZ4_OQwK8Ao8jGHBb5x-w9tn7kFsW1tFt9eiCx-MjRL3e4z7EnBXSqEfARnsD8TU66fWQ4M3TfYG-f_r4bfa5uLuff5ld3RWGEyELYY1knPC8f982hLOuJYxLq7uK97LrqBWt1boVoCtb57q3LeNdJ4BpbqBlF-jdITfP_72BNKqVSwaGQXsIm6RkI0RVM1FlpTwoTd40RehV_shKx72iRE2w1VJNHNXEVE2w1T_Yapetb5-GbLoV2KPxmW4WvD8I_rgB9v8drK5uZvdTmQOKQ4BLI-yOATr-Uo1golY_vs7V9XyxuP5AFuqW_QUlD58d</recordid><startdate>201106</startdate><enddate>201106</enddate><creator>YEE, Chi-hang</creator><creator>NG, Chi-fai</creator><creator>WONG, Annie YF</creator><creator>CHAN, Chi-kowk</creator><creator>HOU, See-ming</creator><creator>YIP, Sidney KH</creator><general>Blackwell Publishing Asia</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201106</creationdate><title>Zoledronic acid to prevent bone loss in Chinese men receiving androgen deprivation therapy for prostate cancer</title><author>YEE, Chi-hang ; NG, Chi-fai ; WONG, Annie YF ; CHAN, Chi-kowk ; HOU, See-ming ; YIP, Sidney KH</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4078-7dc83404743f96043b90348dab24f8bb1d79daa97ea2d579dfd934bb7e3a4ce93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Androgen Antagonists - adverse effects</topic><topic>androgen deprivation therapy</topic><topic>Asian Continental Ancestry Group</topic><topic>Bone Density - drug effects</topic><topic>Bone Density Conservation Agents - therapeutic use</topic><topic>Diphosphonates - therapeutic use</topic><topic>Humans</topic><topic>Imidazoles - therapeutic use</topic><topic>Male</topic><topic>Orchiectomy - adverse effects</topic><topic>Osteoporosis - chemically induced</topic><topic>Osteoporosis - prevention & control</topic><topic>prostate cancer</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>zoledronic acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>YEE, Chi-hang</creatorcontrib><creatorcontrib>NG, Chi-fai</creatorcontrib><creatorcontrib>WONG, Annie YF</creatorcontrib><creatorcontrib>CHAN, Chi-kowk</creatorcontrib><creatorcontrib>HOU, See-ming</creatorcontrib><creatorcontrib>YIP, Sidney KH</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Asia-Pacific journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YEE, Chi-hang</au><au>NG, Chi-fai</au><au>WONG, Annie YF</au><au>CHAN, Chi-kowk</au><au>HOU, See-ming</au><au>YIP, Sidney KH</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Zoledronic acid to prevent bone loss in Chinese men receiving androgen deprivation therapy for prostate cancer</atitle><jtitle>Asia-Pacific journal of clinical oncology</jtitle><addtitle>Asia Pac J Clin Oncol</addtitle><date>2011-06</date><risdate>2011</risdate><volume>7</volume><issue>2</issue><spage>168</spage><epage>173</epage><pages>168-173</pages><issn>1743-7555</issn><eissn>1743-7563</eissn><abstract>Aim: To explore the bone mineral density (BMD) preservation effect of zoledronic acid and its renal safety and tolerability in Chinese patients with prostate cancer on androgen deprivation therapy (ADT).
Methods: Overall 26 prostate cancer patients with ADT were given zoledronic acid 4 mg by a 15‐min i.v. infusion every 3 months for up to 12 months. Assessment was made at baseline and at 3, 6, 9 and 12 months. Dual‐energy X‐ray absorptiometry was used to measure the BMD of the lumbar spine and the femoral neck at baseline and 12 months.
Results: A total of 23 of 26 recruited patients completed the study. Seven patients had bone metastases. The overall mean increase in BMD (T‐score) of the lumbar spine and femoral head from baseline to follow up at 12 months was significant (−2.32 ± 0.98 to −2.03 ± 1.08, P = 0.02 and −1.77 ± 0.72 to −1.63 ± 0.76, P = 0.01, respectively). In subgroup analyses, significant BMD improvement was observed independent of the status of bone metastasis and the means of ADT. Zoledronic acid had no adverse effect on renal function. Adverse events related to zoledronic acid were minimal.
Conclusion: Zoledronic acid administered every 3 months significantly increased BMD in prostate cancer patients receiving ADT. It had a satisfactory adverse event profile and imposed minimal risk on patients' renal function.</abstract><cop>Melbourne, Australia</cop><pub>Blackwell Publishing Asia</pub><pmid>21585697</pmid><doi>10.1111/j.1743-7563.2011.01388.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1743-7555 |
| ispartof | Asia-Pacific journal of clinical oncology, 2011-06, Vol.7 (2), p.168-173 |
| issn | 1743-7555 1743-7563 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_867725372 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged Androgen Antagonists - adverse effects androgen deprivation therapy Asian Continental Ancestry Group Bone Density - drug effects Bone Density Conservation Agents - therapeutic use Diphosphonates - therapeutic use Humans Imidazoles - therapeutic use Male Orchiectomy - adverse effects Osteoporosis - chemically induced Osteoporosis - prevention & control prostate cancer Prostatic Neoplasms - drug therapy zoledronic acid |
| title | Zoledronic acid to prevent bone loss in Chinese men receiving androgen deprivation therapy for prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T21%3A55%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Zoledronic%20acid%20to%20prevent%20bone%20loss%20in%20Chinese%20men%20receiving%20androgen%20deprivation%20therapy%20for%20prostate%20cancer&rft.jtitle=Asia-Pacific%20journal%20of%20clinical%20oncology&rft.au=YEE,%20Chi-hang&rft.date=2011-06&rft.volume=7&rft.issue=2&rft.spage=168&rft.epage=173&rft.pages=168-173&rft.issn=1743-7555&rft.eissn=1743-7563&rft_id=info:doi/10.1111/j.1743-7563.2011.01388.x&rft_dat=%3Cproquest_cross%3E867725372%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=867725372&rft_id=info:pmid/21585697&rfr_iscdi=true |